This is a continuation of an existing, well-functioning and absolutely essential Core. During the previous funding period, the Core provided extensive biostatistical and data management support to all five projects, to both the Pathology Core and the Tumor Bank Core, and to several of the Developmental Projects, resulting in more than 30 coauthored publications, many in high impact journals. All projects in our new SPORE application will require substantial statistical support for a range of preclinical and clinical experiments. In our experience, centralized biostatistical support ensures that the biostatisticians are completely familiar with all aspects of the Projects and Cores. This provides continuity, increases efficiency, and ensures that appropriate methods are applied.
The specific aims of the Core B (Biostatistics and Data Management) are to: (1) Provide comprehensive biostatistical and bioinformatical consultation, data analysis and reporting;(2) Provide comprehensive support for conduct and analysis of clinical trials, including data quality control and monitoring, interim monitoring and analysis of data, final analysis, and reporting;(3) Develop and maintain databases and database applications in support of Projects and Cores. The SPORE benefits greatly from having a dedicated and experienced team of analysts with a range of skills. For example, analysis of microarray experiments is especially demanding and complex and will require both biostatistical and bioinformatic expertise. Core analysts are active participants in all aspects of the SPORE. Sample size considerations, experimental designs, and overviews of planned analyses for all projects were prepared in collaboration with the Core, and are provided within each project and specific aim. In addition, deep understanding of Project and Core data and analysis needs, in turn, drives database development, ensuring that database solutions meet the broad as well as project-specific needs of the SPORE. Core personnel can also help the investigators design new studies and test new hypotheses that may arise by cross-fertilization of these related projects. Finally, Core leaders are highly experienced biostatisticians, who have longstanding collaborative relationships with all SPORE investigators and other Core leaders, and who are members of the Biostatistics Shared Resource of the Dan L. Duncan Cancer Center at Baylor College of Medicine, thus facilitating a close integration with the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058183-18
Application #
8374586
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2013-05-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
18
Fiscal Year
2012
Total Cost
$222,803
Indirect Cost
$72,398
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications